A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-28

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open, multi-cohort phase II clinical trial, the overall design is divided into two parts: dose confirmation stage and expansion stage. Dose confirmation stage is to evaluate the safety and tolerability of three dosing regimenes of docetaxel polymer micelle for injection in patients with advanced esophageal cancer, and to determine the best dosing regimenes for entering the expansion stage. The expansion stage iwas used to evaluate the efficacy and further safety of the best dosing regimen identified in the dose confirmation stage in patients with advanced solid tumors. All subjects in the dose confirmation stage and expansion stage will continue treatment according to the injection docetaxel micelle regimen they received at enrollment until the disease progresses or the investigator determines that continuing treatment with the study drug will not benefit, or any intolerable toxicity occurs, or they voluntarily withdraw, or for other reasons, whichever occurs first.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Docetaxel and S-1 for Advanced Esophageal Cancer

NCT01693432

Esophageal Neoplasms

UNKNOWN PHASE2

A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma

NCT02915965

Stage II and III Esophageal Squamous Cell Carcinoma

UNKNOWN PHASE2

Neoadjuvant Immunotherapy to ESCC

NCT04625543

Esophagus SCC

WITHDRAWN PHASE2

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

NCT06136988

Locally Advanced Unresectable Esophageal Squamous Carcinoma

NOT_YET_RECRUITING PHASE1/PHASE2

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

NCT02465736

Esophageal Squamous Cell Carcinoma Esophageal Cancer Oesophageal Cancer

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Docetaxel Polymeric Micelles for Injection

Group Type EXPERIMENTAL

Docetaxel Polymeric Micelles for Injection

Intervention Type DRUG

Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docetaxel Polymeric Micelles for Injection

Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female aged 18\~75 years old
* Patients with histopathologically or cytologically confirmed advanced or metastatic solid tumors who have failed or are not eligible for standard therapy in the past
* Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* There are measurable tumors(RECIST 1.1)

Exclusion Criteria

* Previous palliative chemotherapy with docetaxel failed
* Central nervous system metastasis or meningeal metastasis with clinical symptoms
* Has a history of serious cardiovascular disease
* A history of immunodeficiency, including a positive test for human immunodeficiency virus (HIV)
* Active hepatitis B (HBsAg positive, HBV DNA\>; ULN) or hepatitis C (HCV antibody positive and HCV RNA\>ULN)
* Has a history of allergies to yew medications
* Pregnant or lactating women
* The investigator considered that there were other reasons for the subjects' ineligibility for this clinical study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No